Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | MT-6402 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - resistant | MT-6402 | Preclinical - Cell culture | Actionable | In a preclinical study, MT-6402 treatment demonstrated cytotoxicity in a panel of CD274 (PD-L1)-positive cancer cell lines in culture (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Phase I study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing advanced solid tumors | Full reference... |